Genetic engineering News 24 September 2019

First mAb produced via fully continuous biomanufacturing

​

In February 2019 BiosanaPharma received approval from the Australian Bellberry Human Research Ethics Committee to begin a Phase I clinical trial for a biosimilar version of omalizumab, the first monoclonal antibody (mAb) produced with a fully continuous biomanufacturing process.